Kornimate/medical-research-clean huggingface dataset:
high-intensity focused ultrasound focal ablation in treating patients with progressive prostate cancer

Conditions: Prostate Cancer; Sexual Dysfunction

Summary: rationale: high-intensity focused ultrasound focal ablation uses high-energy sound waves to kill tumor cells. purpose: this phase ii trial is studying the side effects of high-intensity focused ultrasound focal ablation and to see how well it works in treating patients with progressive prostate cancer.

objectives: primary * to evaluate the side effects of high-intensity focused ultrasound (hifu) ablation in men with non-metastatic progressive prostate cancer. * to evaluate the quality of life of patients treated with this regimen. secondary * to determine the success of index lesion ablation with hifu at 6 months after treatment by demonstrating the absence of cancer in the treated or ablated area by transrectal ultrasound biopsy. * to evaluate the prostate-specific antigen kinetics after index lesion ablation in patients treated with this regimen. * to evaluate the proportion of men who require androgen blockade at 12 months of follow-up. outline: patients undergo focal ablation with high-intensity focused ultrasound (hifu) ablation on day 1. treatment may repeat at 6 months in patients with progressive disease. blood samples and prostate biopsies are collected periodically for further analysis. patients complete questionnaires (ipss, ipss-qol, ics, iief-5, and fact-p) at baseline and periodically during study.

Eligibility criteria:
disease characteristics: * histologically confirmed prostate cancer by transrectal or transperineal template prostate biopsies * stage ≤ t3bn0m0 * gleason grade ≤ 8 * serum psa ≤ 20 ng/ml * bone scan- or cross-sectional imaging-negative for metastatic or nodal (outside prostate) disease * no metastatic disease and/or nodal spread by ct scan or mri * index lesion or other secondary lesions with a volume ≥ 0.5 cc by mri * no prostatic calcification and cysts (on transrectal ultrasound) that would interfere with effective delivery of therapy patient characteristics: * able to tolerate a transrectal ultrasound * not allergic to latex * fit for major surgery as assessed by a consultant anaesthetist * able to have mri scanning (i.e., none of the following conditions: severe claustrophobia, permanent cardiac pacemaker, metallic implant, etc.) prior concurrent therapy: * no prior radiotherapy * no androgen suppression and/or hormone treatment within the past 12 months * no prior significant rectal surgery preventing insertion of transrectal high-intensity focused ultrasound (hifu) probe (decided on the type of surgery in individual cases) * no prior transurethral resection of the prostate (or equivalent procedures) within the past 2 years * no prior hifu, cryosurgery, thermal, or microwave therapy to the prostate

Keywords: sexual dysfunction stage i prostate cancer stage iib prostate cancer stage iia prostate cancer stage iii prostate cancer
post-operative thoracolumosacral orthosis for pjk

Conditions: Proximal Junctional Kyphosis; Adult Spinal Deformity Surgery; Thoracolumbosacral Orthosis

Summary: proximal junctional kyphosis (pjk) is a common post-operative radiographic finding after surgery for adult spinal deformity (asd) patients. although the clinical relevance of isolated pjk is unclear, pjk can progress to symptomatic proximal junctional failures which requires a large revision surgery. currently, post-operative bracing with a thoracolumbosacral orthosis (tlso) is common practice after spinal deformity surgery, however the efficacy of this in preventing pjk is unknown. this multi-center randomized control trial identified 84 patients undergoing thoracolumbosacral fusion for asd and plans to study the efficacy of a novel post-operative tlso in preventing the development of pjk as defined by the proximal junctional angle on 6-month post-operative x-rays.


Eligibility criteria:
inclusion criteria: * 30-75-years-old * undergoing primary thoracolumbosacral fusion for asd with an upper instrumented vertebrae (uiv) between t8-l2 and lower instrumented vertebrae (liv) of s1 or the ilium. exclusion criteria: * osteoporosis (defined as a t-score \<-2.5 at the time of surgery) * body mass index (bmi) \>35 kg/m2 * revision fusions * fusions for trauma * those with a neuromuscular etiology for their deformity (i.e. parkinson's disease, cerebral palsy, post-stroke, etc.) * an underlying inflammatory arthropathy
potential effects of omega 3 supplementation on cardiomyocytes membranes for patients with coronary atherosclerosis?

Conditions: Coronary Atherosclerosis

Summary: to show the existence of a atrial cardiomyocytes membranes modification in omega-3 supplemented patients with coronary atherosclerosis.

very few human data are currently available on the fatty acid composition of cardiomyocytes membranes. preoperative omega-3 supplementation for patients undergoing cardiac surgery with cardiopulmonary bypass is correlated with a decreased frequency of postoperative complications in type of arrhythmia atrial fibrillation. atrial fibrillation is the most common complication: 30 to 50% after myocardial revascularization. the occurrence of atrial fibrillation increases morbidity and mortality after surgery for sure. the pathophysiological mechanisms of common atrial fibrillation treated in heart rhythm units are different from those of postoperative atrial fibrillation. indeed, atrial fibrillation is a common disease primarily of the left atrium, although atrial fibrillation after cardiac surgery is a multifactorial disease with implication of various pathogens such as inflammation without precise anatomical support. the preventive use of polyunsaturated fatty acids omega-3 long-chain (lc-agpiω3), prior cardiac surgery is far from widespread due to a lack of information dissemination, by insufficient number of published studies, despite the existence of a number of ongoing clinical trials and a complete ignorance of biological mechanisms of action. a human clinical study is needed. in a context of cardiac surgery with cardiopulmonary bypass and without deleterious side effects of preoperative enrichment in omega-3, it seems appropriate to conduct a feasibility study to provide information on structural changes in membranes of cardiomyocytes.

Eligibility criteria:
inclusion criteria: * men without diabetes, * over 50 years with overweight (bmi greater than 25) and * without severe obesity (bmi less than 40) * patients who have given their written consent, * the beneficiary of a social security system. * elective cardiac surgery with sternotomy and cardiopulmonary bypass for coronary artery bypass graft. exclusion criteria:

Keywords: elective cardiac surgery with sternotomy and cardiopulmonary bypass for coronary artery bypass graft.
invasives aspergillosis in acute myeloid leukemia

Conditions: Acute Myeloid Leukemia; Invasive Aspergillosis

Summary: patients with acute myeloid leukemia (aml) are at risk to develop severe infections whose invasive aspergillosis (ia). these infections are leading to an important morbidity and mortality. antifungal prophylaxis is recommended by posaconazole for aml patients during neutropenia induced by induction chemotherapy. their application is not uniform.

invasive aspergillosis are frequent infections in hematological malignancy in particular during neutropenia induced by chemotherapy. their incidence ranged between 5 to 25% according to the literature. mortality may reach 30%. our study described ia incidence in aml patients treated by intensive chemotherapy depending on antifungal prophylaxis by posaconazole. from 2009 to 2011, any patients received antifungal prophylaxis. from 2012 to 2015, patients received posaconazole during induction and salvage chemotherapy. during the all study period, efficacy of posaconazole is evaluated according to construction/demolition periods in hospital. all patients are hospitalized in high efficiency particulate air (hepa) filtration system.

Eligibility criteria:
inclusion criteria: * \> 18 years * acute myeloid leukemia * intensive chemotherapy (induction, consolidation, salvage, bone marrow transplantation) exclusion criteria: * \< 18 years * pregnancy * no intensive chemotherapy (palliative treatment, azacytidine...)
effects of fear of falling on physical performance and quality of life in children with duchenne muscular dystrophy

Conditions: Neuromuscular Diseases; Duchenne Muscular Dystrophy; Dystrophy; Dystrophy, Muscular

Summary: for ambulatory children with dmd, physiotherapy is aimed at protecting ambulation, improving motor performance to the best level and increasing quality of life. the investigators think that the treatment of children with duchenne muscular dystrophy may become more effective with physiotherapy programs based on the comprehensive physiotherapy evaluation results, including the evaluation of fear of falling. this study investigates the fear of falling in children with duchenne muscular dystrophy and questioning whether their fear of falling affects their quality of life and their physical performance.


Eligibility criteria:
inclusion criteria: * diagnosed with duchenne muscular dystrophy by a pediatric neurologist, * being volunteer, * being between 6 and 15 years old, * being between levels 1-5 according to the brooke lower extremity functional classification developed to classify lower extremity functions in children with dmd, * being able to cooperate with the physiotherapist's directives. exclusion criteria: * being between levels 6-10 (children who do not have independent ambulatory ability) according to the brooke lower extremity functional classification, * not being able to cooperate with the physiotherapist's directives, * end of the volunteering.

Keywords: physiotherapy and rehabilitation fear of falling quality of life
a strategy for gallstone expulsion through dietary therapy

Conditions: Gallbladder Stone

Summary: this study is a double-blind, prospective, single-center controlled trial conducted at a tertiary hospital, aiming to determine whether dietary therapy can effectively expel gallstones.

gallstones are a common clinical condition, and their prevalence has been increasing globally in recent years. gallstone formation is a result of various combined factors, and in its early stages, gallstones often exist in a sludge-like form. currently, there is no definitive research on whether gallbladder sludge can be effectively expelled through medication or dietary therapy. therefore, the investigators are conducting a double-blind, prospective, single-center controlled trial to verify whether gallbladder sludge-like stones can be effectively expelled using dietary therapy.

Eligibility criteria:
inclusion criteria: * gallbladder sludge-like stones with a maximum stone diameter of less than 2 mm exclusion criteria: * history of ercp (endoscopic retrograde cholangiopancreatography) * previous gallstone removal surgery with gallbladder preservation * history of acute or chronic pancreatitis, cholangitis * mirizzi syndrome * history of gastrointestinal surgery * gastrointestinal obstruction * dysfunction of the sphincter of oddi * gallbladder neck polyps * abnormal gallbladder structure * gallbladder mass * biliary infection or stones * congenital biliary abnormalities * biliary injury or surgery * biliary tumors * gastrointestinal bleeding, liver cirrhosis, or other malignant diseases * significant arrhythmia, bradycardia, or atrioventricular block * severe hypertension, liver or kidney insufficiency * immune, endocrine, hematological, or mental disorders * severe cerebrovascular disease * allergy to relevant foods * pregnant or breastfeeding women * unwillingness or inability to consent to participation

Keywords: gallstone gallbladder function cholecystitis ultrasound examination
linking tau pet to medial temporal lobe subregions with high resolution mri

Conditions: Mild Cognitive Impairment

Summary: the investigators will conduct a tau pet scan in cognitively normal older adults and patients with mild cognitive impairment (mci), enrolled in the national alzheimer's coordinating center (nacc) study at the university of pennsylvania's penn memory center/alzheimer's disease core center (pmc/adc).

this is a cross-sectional and longitudinal study using the radiotracer \[18f\]-pi-2620 to determine the relationship of tau pathology to both cross-sectional and longitudinal clinical and biomarker data of nacc cohort participants who are cognitively normal or mci. all subjects will already be part of the longitudinal cohort study, known as the "nacc" cohort, of the pmc/adc (protocol 068200). participants will provide informed consent for this protocol before beginning any study procedures. after screening assessments, participants will undergo pet scan imaging with \[18f\]pi-2620. there will be one follow-up \[18f\]pi-2620 pet scan approximately 18 +/- 6 months after bas eline scan.

Eligibility criteria:
inclusion criteria: * males and females ≥ 60 years of age. * part of the nacc longitudinal cohort (irb# 068200) of the pmc/adcc with consensus conference designation of cognitively normal or mild cognitive impairment (mci) or alzheimer's disease (ad) possible or probable. * nacc longitudinal visit completed or scheduled within 6 months before or after enrollment in this study. * women must be post-menopausal or surgically sterile. * an amyloid pet scan, completed as a part of the nacc protocol (irb# 825943), must be performed or scheduled within 12 months before or after the \[18f\]pi-2620 pet scan. * a brain mri, completed as a part of nacc protocol (irb# 068200), must be performed or scheduled within 6 months before or after the \[18f\]pi-2620 pet scan. scan should be of adequate research quality, including 3 tesla and/or 7 tesla high-resolution imaging of mtl structure. exclusion criteria: * have any medical or psychiatric conditions that, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study. * have evidence of structural abnormalities such as major stroke or mass on mri that is likely to interfere with analysis of the pet scan. * inability to tolerate or contraindication to imaging procedures in the opinion of an investigator or treating physician. * have a history of significant or ongoing alcohol abuse or substance abuse or dependence based on medical record review or self-reported. the inclusion / exclusion criteria will be ascertained through self-report in conjunction with any medical history available through the participant's medical or research records (epic or the adc database)
intrathecal morphine for postoperative analgesia following laparoscopic bariatric surgery

Conditions: Postoperative Pain

Summary: this study compares the use of intrathecal morphine, to multimodal analgesic techniques for postoperative pain management following laparoscopic bariatric surgery.


Eligibility criteria:
inclusion criteria: * american society of anesthesia (asa) ii-iii patients. * aged 30-50 years. * the body mass index (bmi) of the patients needed to be over 40 kg/m² or over 35 kg/m² with at least one comorbidity. exclusion criteria: * patients with a known allergy to the study drugs. * advanced cardiac, respiratory, renal or hepatic disease. * coagulation disorders. * infection at or near the site of intrathecal injection. * drug or alcohol abuse. * psychiatric illnesses that may interfere with perception and assessment of pain.
coaction trial - combination androgen blockade in intermediate to high-risk prostate cancer

Conditions: Prostate Cancer

Summary: a randomized trial of neoadjuvant leuprorelin, darolutamide or both prior to radical prostatectomy for intermediate or high-risk prostate cancer. prospective, randomized, parallel group, open-label with blinded endpoint adjudication multicenter clinical trial.to assess, among patients with unfavorable intermediate to high-risk prostate cancer, whether a neoadjuvant combined treatment with leuprorelin (leuprorelin) and darolutamide is superior to monotherapy in terms of complete or almost complete pathological response.a total of 144 patients with unfavorable intermediate to high-risk prostate cancer scheduled for radical prostatectomy with extended pelvic lymph node dissection will be randomized 1:1:1 to oral darolutamide, sc leuprorelin (leuprorelin) or both (48 patients per arm) for 24 weeks.


Eligibility criteria:
inclusion criteria: * men ≥18 years of age; * histologically confirmed unfavorable intermediate or high/very high risk non metastatic (by conventional imaging) prostate adenocarcinoma intended for surgery without neuroendocrine differentiation or small cell features; * unfavorable intermediate-risk: * isup grade 3, and/or \> 50% positive biopsy cores and/or at least two intermediate-risk factors. intermediate-risk factors: * clinical tumor stage t2b or t2c (mri based); * isup grade 2 or 3; * prostate-specific antigen (psa) level of 10-20 ng/ml. * high-risk or very high-risk: * ≥ct3a (mri based) or isup 4-5 or psa\>20 ng/ml; * cn1. * ecog 0-1; * baseline testosterone \> 230 ng/dl; * no prior prostate cancer treatment; * sexually active male subjects must agree to use condoms as an effective barrier method and refrain from sperm donation, and/or their female partners of reproductive potential to use a method of effective birth control, during the treatment with darolutamide and for 1 week after the end of treatment with darolutamide to prevent pregnancy; * written informed consent. exclusion criteria: * unresectable prostate cancer; * histology of small cell carcinoma prostate cancer or adenocarcinoma with neuroendocrine features; * any prior prostate cancer treatment; * any active infection requiring iv antibiotics; * known additional malignancy that has a life-expectancy \< 2 years; * had any of the following within 6 months before randomization: stroke, myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, heart failure with new york heart association class functional iii or iv; * uncontrolled severe hypertension as indicated by a resting systolic bp ≥ 180 mmhg or diastolic bp ≥ 110 mmhg despite medical management; * a gastrointestinal (gi) disorder or procedure which is expected to interfere significantly with absorption of darolutamide; * inability to swallow oral medications; * receipt of medications (e.g. finasteride, dutasteride) or agents that are likely to alter serum psa levels within \<= 42 days or 5 half-lives prior to registration, whichever is shorter.

Keywords: prostate cancer radical prostatectomy darolutamide neoadjuvant
intravitreal avastin versus intravitreal avastin and triamcinolone in central retinal vein occlusion(crvo)

Conditions: Retinovascular Disease

Summary: in this study we intend to evaluate and compare the outcomes of intravitreal avastin versus avastin and triamcinolone on improving the visual acuity and macular edema and late complications of crvo like nvi and nvg.

central retinal vein occlusion (crvo) is a common retinal vascular disorder with potentially complications like reduced vision resulting from extensive intraretinal hemorrhage, retinal ischemia and persistent macular edema and neovascular glaucoma secondary to iris neovascularization. macular edema is a common cause of severe visual loss in both branch retinal vein occlusion (brvo) and central retinal vein occlusion (crvo). natural history data indicate that crvo patients presenting with poor visual acuity (_20/200) have an 80% chance of being left with visual acuity less than 20/200 at final visit, whether the crvo is ischemic or nonischemic at presentation. treatments that target the secondary effects of venous occlusion, such as grid laser photocoagulation for macular edema and prophylactic panretinal laser photocoagulation for nonperfused crvo, were shown to be ineffective in improving visual acuity in the central vein occlusion study (cvos). although panretinal photocoagulation is advocated for reducing the risk of neovascular glaucoma in patients with ischemic crvo, recent clinical trials have failed to demonstrate any significant benefit with laser photocoagulation in the treatment of macular edema due to crvo. a number of other treatment options are sometimes used in cases of crvo, such as oral corticosteroids, intravitreal steroids, vitrectomy, hemodilution, intravitreal tissue plasminogen activator, hyperbaric oxygen, and laser or surgical chorioretinal anastomosis. studies demonstrating the effectiveness of these treatments are inconclusive, although some benefits have been suggested in recent reports. in recent studies the benefit of antivegf agents in improving the macular edema due to crvo have been shown. in this study we are going to compare the effect of intravitreal antivegf (avastin) with combination of avastin and triamcinolon in improving the visual acuity and macular thickness in patients with recent (less than 6 months) crvo.

Eligibility criteria:
inclusion criteria: * crvo with duration less than 6 months exclusion criteria: * vision less than 20/320 and vison more than 20/50 * history of galucoma and diabetic retinopathy * previous laser or intravitreal treatment * any media opacity that prevents funduscopy

Keywords: crvo intravitreal avastin intravitreal triamcinolone
prognostic factors in epiretinal membrane surgery

Conditions: Epiretinal Membranes

Summary: retrospective interventional case series study reporting preoperative clinical and anatomical factors associated with visual recovery 1 year after combined cataract and idiopathic epiretinal membrane surgery. age, duration of symptoms, and preoperative best corrected visual acuity appeared to be reliable prognostic factors. combining these factors with analysis of the photoreceptors' inner and outer segments junction in spectral-domain optical coherence tomography provides a predictive score to estimate individual chances of good visual recovery


Eligibility criteria:
inclusion criteria: * symptomatic idiopathic epiretinal membrane operated on between april 2009 and september 2012 at the university hospital of dijon, france. * all patients signed informed consent for the surgical procedure. exclusion criteria: * patients were excluded if they presented any cause of secondary epiretinal membrane (including diabetic retinopathy, vein occlusion, ocular inflammation, retinal detachment, or previously vitrectomized eye), high myopia (axial length ≥ 26 mm or spherical equivalent ≥ 6 diopters), severe media opacities with weak sd-oct signal strengths, or any macular or optic nerve disease. patients with a follow-up of less than 12 months were excluded and only one eye was included in those with bilateral epiretinal membranes.